Asian Pacific Society of Cardiology Position Statement on the Use of Transcatheter Aortic Valve Implantation in the Management of Aortic Stenosis
Jonathan Yap,Kentaro Hayashida,Michael Kang Yin Lee,Dion Stub,Jimmy Kim Fatt Hon,Kay Woon Ho,Sidney Lo,Ashok Seth,Hyo-Soo Kim,Nattawut Wongpraparut,Quang Ngoc Nguyen,Timothy C. Dy,Mann Chandavimol,See Hooi Ewe,Wei-Hsian Yin,Yung-Tsai Lee,Edgar L. Tay,Karl Poon,Mao Chen,Angus Chui,Simon Cheung-Chi Lam,Ravinder Singh Rao,Masaki Izumo,Rajesh Nair,Gilbert HL Tang,Minoru Tabata,Shaiful Azmi Yahaya,Kenny YK Sin,Duk-Woo Park,Jianan Wang,Jack Tan Wei Chieh
DOI: https://doi.org/10.1016/j.jacasi.2024.10.001
2024-01-01
JACC Asia
Abstract:Transcatheter aortic valve implantation (TAVI) has been established as an effective treatment modality in patients with severe aortic stenosis and the uptake of TAVI is rapidly growing in the Asia-Pacific region. However, there exists a heterogeneity in the management of aortic stenosis and the use of TAVI among countries in the region. Reasons for these differences include anatomical variations, disparity in healthcare resources and infrastructure and the lack of consensus on the optimal management of aortic stenosis in the Asia-Pacific region. Hence, an Asian Pacific Society of Cardiology (APSC) working group, including a multidisciplinary group of general and interventional cardiologists, cardiac surgeons and imaging specialists, developed a position statement on the recommendations for TAVI in the management of aortic stenosis. The APSC expert panel reviewed and appraised the available evidence using the Grading of Recommendations Assessment, Development, and Evaluation system. Recommendations were developed and put to an online vote. Consensus was reached when 80% of votes for a given recommendation were in support of ‘agree’ or ‘neutral.’ The resulting 28 statements provide guidance for clinical practitioners in the region on the use of TAVI in the treatment of patients with aortic stenosis.